Heart Acme Secures Tens of Millions in Pre-A Funding Led by Chende Capital to Advance Non-Implantable Cardiovascular Solutions

CVSource, July 26 – Shanghai XinZhi Medical Technology Co., Ltd. has completed its Pre-A financing round, securing tens of millions of RMB from Chende Capital.

It is reported that after securing Pre-A round financing, XinZhi Medical will focus on enriching its product portfolio. Drug-coated balloons are expected to see broader applications in the future, expanding from coronary drug-coated balloons to include those for small vessels, bifurcation lesions, and certain de novo lesions. XinZhi will continue to develop more valuable "intervention without implantation" products comprehensively within the cardiovascular field.

Public records indicate that XinZhi Medical, established in May 2017, is a developer of cardiovascular interventional therapies dedicated to promoting technological innovation in this field. Its meticulously designed and independently developed “Coronary Drug-Coated Balloon” has made significant strides in the treatment of cardiovascular diseases. Leveraging balloon and drug-coating technologies as its platform, the company has become a leading domestic provider of non-implantable interventional solutions.